Zydus Lifesciences Limited (NSE:ZYDUSLIFE)
937.25
-3.30 (-0.35%)
At close: Nov 27, 2025
Zydus Lifesciences Revenue
Zydus Lifesciences had revenue of 61.23B INR in the quarter ending September 30, 2025, with 16.92% growth. This brings the company's revenue in the last twelve months to 244.94B, up 14.01% year-over-year. In the fiscal year ending March 31, 2025, Zydus Lifesciences had annual revenue of 232.42B with 18.90% growth.
Revenue (ttm)
244.94B
Revenue Growth
+14.01%
P/S Ratio
3.85
Revenue / Employee
8.77M
Employees
27,917
Market Cap
943.09B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 232.42B | 36.94B | 18.90% |
| Mar 31, 2024 | 195.47B | 23.10B | 13.40% |
| Mar 31, 2023 | 172.37B | 21.28B | 14.08% |
| Mar 31, 2022 | 151.10B | 7.06B | 4.90% |
| Mar 31, 2021 | 144.04B | 1.50B | 1.06% |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Sun Pharmaceutical Industries | 549.64B |
| Aurobindo Pharma | 325.14B |
| Cipla | 279.66B |
| Apollo Hospitals Enterprise | 232.65B |
| Biocon | 164.76B |
| Glenmark Pharmaceuticals | 159.97B |
| Alkem Laboratories | 138.90B |
| Mankind Pharma | 135.46B |
Zydus Lifesciences News
- 13 days ago - Zydus Lifesciences secures USFDA approval for Leuprolide Acetate Injection - Business Upturn
- 14 days ago - Zydus Lifesciences receives USFDA tentative approval for Diroximel Fumarate capsule, 231 mg - Business Upturn
- 14 days ago - Zydus Lifesciences’ robotic surgical system ‘Andy’ secures CE mark approval - Business Upturn
- 16 days ago - Zydus Lifesciences secures first-ever approval from China’s NMPA for Venlafaxine ER Capsules - Business Upturn
- 20 days ago - Zydus Lifesciences Ltd (BOM:532321) Q2 2026 Earnings Call Highlights: Robust Revenue Growth ... - GuruFocus
- 20 days ago - Q2 2026 Zydus Lifesciences Ltd Earnings Call Transcript - GuruFocus
- 21 days ago - Zydus Lifesciences receives USFDA Orphan Drug Designation for Desidustat to treat beta-thalassemia - Business Upturn
- 22 days ago - Zydus Lifesciences receives ‘No Action Indicated’ classification from USFDA for Ahmedabad SEZ-II facility - Business Upturn